论文部分内容阅读
MHC class Ⅰ (MHC Ⅰ) antigen presentation of exogenous antigens (so called "cross presentation") is a central mechanism of CD8+ cytotoxic T lymphocyte (CTL) responses essentially for successful vaccine-based cancer immunotherapy.